U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C18H21NO4.C8H6O4
Molecular Weight 796.8581
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXYCODONE TEREPHTHALATE

SMILES

OC(=O)C1=CC=C(C=C1)C(O)=O.[H][C@@]23OC4=C5C(C[C@H]6N(C)CC[C@@]25[C@@]6(O)CCC3=O)=CC=C4OC.[H][C@@]78OC9=C%10C(C[C@H]%11N(C)CC[C@@]7%10[C@@]%11(O)CCC8=O)=CC=C9OC

InChI

InChIKey=BTEYIHUKHHAVAN-KDKWOIFOSA-N
InChI=1S/2C18H21NO4.C8H6O4/c2*1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;9-7(10)5-1-2-6(4-3-5)8(11)12/h2*3-4,13,16,21H,5-9H2,1-2H3;1-4H,(H,9,10)(H,11,12)/t2*13-,16+,17+,18-;/m11./s1

HIDE SMILES / InChI

Molecular Formula C18H21NO4
Molecular Weight 315.3636
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C8H6O4
Molecular Weight 166.1308
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321 | https://www.ncbi.nlm.nih.gov/pubmed/23880538 | https://www.drugs.com/oxycodone.html

Oxycodone is a semisynthetic opioid used for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Oxycodone is a highly selective full agonist of the μ-opioid receptor (MOR), with low affinity for the δ-opioid receptor (DOR) and κ-opioid receptor (KOR). After oxycodone binds to the MOR, a G protein-complex is released, which inhibits the release of neurotransmitters by the cell by reducing the amount of cAMP produced, closing calcium channels, and opening potassium channels. After a dose of conventional (instant-release) oral oxycodone, the onset of action is 10–30 minutes, and peak plasma levels of the drug are attained within roughly 30–60 minutes in contrast, after a dose of OxyContin (an oral controlled-release formulation), peak plasma levels of oxycodone occur in about three hours. The duration of instant-release oxycodone is 3 to 6 hours, although this can be variable depending on the individual. Oxycodone in the blood is distributed to skeletal muscle, liver, intestinal tract, lungs, spleen, and brain. Serious side effects of oxycodone include reduced sensitivity to pain (beyond the pain the drug is taken to reduce), euphoria, anxiolysis, feelings of relaxation, and respiratory depression. Common side effects of oxycodone include constipation (23%), nausea (23%), vomiting (12%), somnolence (23%), dizziness (13%), itching (13%), dry mouth (6%), and sweating (5%).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
500.0 nM [EC50]
16000.0 nM [EC50]
4000.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PERCODAN-DEMI

Approved Use

OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.)

Launch Date

-6.224256E11
Primary
PERCODAN-DEMI

Approved Use

OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.)

Launch Date

-6.224256E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
19 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
22.2 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
17.7 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
39.3 ng/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
15.7 ng/mL
5 mg 4 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12.9 ng/mL
3.33 mg 6 times / day steady-state, oral
dose: 3.33 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
105 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
128.2 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
133 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
268.2 ng × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
113.3 ng × h/mL
5 mg 4 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
99 ng × h/mL
3.33 mg 6 times / day steady-state, oral
dose: 3.33 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.9 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
3.55 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.3 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
3.85 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
55%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
55%
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
55%
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55%
5 mg 4 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55%
3.33 mg 6 times / day steady-state, oral
dose: 3.33 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / day single, oral
Studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Co-administed with::
acetaminophen(1950 mg; single)
cocaine(1/4 g; single)
Sources:
healthy, 30 years
n = 1
Health Status: healthy
Age Group: 30 years
Sex: M
Population Size: 1
Sources:
Other AEs: Pulmonary edema...
Other AEs:
Pulmonary edema
Sources:
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 120
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Disc. AE: Nausea, Dizziness...
AEs leading to
discontinuation/dose reduction:
Nausea (grade 1-2, 1.7%)
Dizziness (grade 1-2, 1.7%)
Abdominal pain (grade 1-2, 0.8%)
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Disc. AE: Headache, Vomiting...
AEs leading to
discontinuation/dose reduction:
Headache (grade 1-2, 0.8%)
Vomiting (grade 1-2, 0.8%)
Nausea (grade 1-2, 0.8%)
Somnolence (grade 1-2, 0.8%)
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 63
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 63
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Disc. AE: Nausea, Dizziness...
AEs leading to
discontinuation/dose reduction:
Nausea (grade 1-2, 6.3%)
Dizziness (grade 1-2, 4.8%)
Confusion (grade 1-2, 3.2%)
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Disc. AE: Vomiting, Flu syndrome...
AEs leading to
discontinuation/dose reduction:
Vomiting (grade 1-2, 0.8%)
Flu syndrome (grade 1-2, 0.8%)
Confusion (grade 1-2, 0.8%)
Fatigue (grade 1-2, 0.8%)
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
6 mg 2 times / day single, oral (mean)
Studied dose
Dose: 6 mg, 2 times / day
Route: oral
Route: single
Dose: 6 mg, 2 times / day
Sources:
healthy, mean age 33 years
n = 35
Health Status: healthy
Age Group: mean age 33 years
Sex: M+F
Population Size: 35
Sources:
Disc. AE: Vomiting...
15 mg 1 times / day single, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: single
Dose: 15 mg, 1 times / day
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
healthy, mean age 36 years
n = 40
Health Status: healthy
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
Disc. AE: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting (2.5%)
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
AEs

AEs

AESignificanceDosePopulation
Pulmonary edema
30 mg 1 times / day single, oral
Studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Co-administed with::
acetaminophen(1950 mg; single)
cocaine(1/4 g; single)
Sources:
healthy, 30 years
n = 1
Health Status: healthy
Age Group: 30 years
Sex: M
Population Size: 1
Sources:
Abdominal pain grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 120
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Dizziness grade 1-2, 1.7%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 120
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Nausea grade 1-2, 1.7%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 120
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Headache grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Nausea grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Somnolence grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Vomiting grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Confusion grade 1-2, 3.2%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 63
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 63
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Dizziness grade 1-2, 4.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 63
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 63
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Nausea grade 1-2, 6.3%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 63
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 63
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Confusion grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Fatigue grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Flu syndrome grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Vomiting grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Vomiting 11.4%
Disc. AE
6 mg 2 times / day single, oral (mean)
Studied dose
Dose: 6 mg, 2 times / day
Route: oral
Route: single
Dose: 6 mg, 2 times / day
Sources:
healthy, mean age 33 years
n = 35
Health Status: healthy
Age Group: mean age 33 years
Sex: M+F
Population Size: 35
Sources:
Vomiting 2.5%
Disc. AE
15 mg 1 times / day single, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: single
Dose: 15 mg, 1 times / day
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
healthy, mean age 36 years
n = 40
Health Status: healthy
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
yes
yes
yes
yes (co-administration study)
Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001).
Page: 7.0
yes
yes (co-administration study)
Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001).
Tox targets
PubMed

PubMed

TitleDatePubMed
Opioid formulations: tailoring to the needs in chronic pain.
2001
Time-release analgesic drug causes fatal overdoses in United States.
2001 Aug
"No, Duke. No divorce".
2001 Aug 20
A curse and a cure. Is the crackdown on an abused drug causing needless suffering?
2001 Aug 6
Opioid analgesic prescribing and use - an audit of analgesic prescribing by general practitioners and The Multidisciplinary Pain Centre at Royal Brisbane Hospital.
2001 Dec
On the frontlines of old battles.
2001 Jul
Identification of ozone-oxidation products of oxycodone by electrospray ion trap mass spectrometry.
2001 Jul
Stability indicating HPLC method for the estimation of oxycodone and lidocaine in rectal gel.
2001 Jul 31
Addressing OxyContin abuse.
2001 Jul-Aug
Preoperative diclofenac is a useful adjunct to spinal anesthesia for day-case varicose vein repair.
2001 Jul-Aug
Narcotic analgesics for dental pain: available products, strengths, and formulations.
2001 Mar-Apr
The use of oxycodone in cancer-related pain: a literature review.
2001 Nov
Clinical case study.
2001 Nov-Dec
Acetaminophen, aspirin, or Ibuprofen in combination analgesic products.
2001 Nov-Dec
Opioid therapy for chronic painful conditions.
2001 Oct
States respond to growing abuse of painkiller.
2001 Oct-Nov
Controlled-release oxycodone hydrochloride (OxyContin).
2001 Sep
Managing postoperative pain.
2001 Sep
Valdecoxib.
2002
Oxycodone/ibuprofen.
2002
Hydromorphone for acute and chronic pain.
2002
Oxy's offspring.
2002 Apr 22
Minimal interaction between gatifloxacin and oxycodone.
2002 Aug
Nasal administration of opioids for pain management in adults.
2002 Aug
Treatment of postherpetic neuralgia: a systematic review of the literature.
2002 Feb
Comparison of pre- and postoperative administration of ketoprofen for analgesia after tonsillectomy in children.
2002 Feb
The influence of anaesthesia and surgery on the circadian rhythm of melatonin.
2002 Jan
Perioperative management in children with sickle cell disease undergoing laparoscopic surgery.
2002 Jan-Mar
Gateways to clinical trials.
2002 Jul-Aug
OxyContin and neonatal abstinence syndrome.
2002 Jun
Comparison of the opioid-sparing efficacy of diclofenac and ketoprofen for 3 days after knee arthroplasty.
2002 Mar
There is no accounting for accountability.
2002 Mar
Validity and reliability of three commercially available breath-by-breath respiratory systems.
2002 Mar
[Chronic pain of the musculoskeletal system. Make your patients move!].
2002 Mar 14
Pain management after major orthopaedic surgery: current strategies and new concepts.
2002 Mar-Apr
OxyContin Use and Abuse.
2002 Mar-Apr
From physician to inmate.
2002 May
The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery.
2002 May
Oral ondansetron, tropisetron or metoclopramide to prevent postoperative nausea and vomiting: a comparison in high-risk patients undergoing thyroid or parathyroid surgery.
2002 May
Venous malformations associated with central pain: report of a case.
2002 Nov
Simultaneous quantitation of opioids in blood by GC-EI-MS analysis following deproteination, detautomerization of keto analytes, solid-phase extraction, and trimethylsilyl derivatization.
2002 Oct
Detection of cocaine analytes and opiates in nails from postmortem cases.
2002 Oct
Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases.
2002 Oct
Propacetamol as adjunctive treatment for postoperative pain after cardiac surgery.
2002 Oct
Massive OxyContin ingestion refractory to naloxone therapy.
2002 Oct
Induced hypothermia for drug overdose.
2002 Sep
[Pain therapy in rheumatic diseases. Oxycodon is not a weak opioid].
2002 Sep 12
Paravertebral somatic nerve block compared with peripheral nerve blocks for outpatient inguinal herniorrhaphy.
2002 Sep-Oct
Review: tricyclic antidepressants, capsaicin, gabapentin, and oxycodone are effective for postherpetic neuralgia.
2002 Sep-Oct
Oxycontin--misuse and abuse.
2002 Summer
Patents

Sample Use Guides

For opioid naïve patients, initiate treatment with 5 mg to 15 mg every 4 to 6 hours as needed for pain.
Route of Administration: Oral
Human embryonic kidney (HEK)-293 were used for activity evaluation. Receptor G protein-mediated responses were determined by measuring changes in cAMP using the cAMP–homogenous timeresolved fluorescence kit (Cisbio, Codolet, France). MOR, KOR, DOR all couple to Gai so G protein coupling was measured as inhibition of forskolin-stimulated cAMP accumulation in the presence of 1.5 mkM NKH-477 (water-soluble forskolin, Tocris catalog #1603) and 500 mkM 3-isobutyl-1-methylxanthine (IBMX). cAMP accumulation assays were run in parallel with b-arrestin-2 recruitment, using the same cells, drug dilutions, and assay buffers [1% dimethylsulfoxide (DMSO), F12 Ham’s buffer] to ensure accurate assay-to-assay comparisons of data. Plates were read using a time-resolved fluorescence ratio (665 nm/620 nm) on a PheraStar plate reader
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:50:40 UTC 2023
Edited
by admin
on Wed Jul 05 22:50:40 UTC 2023
Record UNII
M04XWV43UF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXYCODONE TEREPHTHALATE
MART.   ORANGE BOOK   USP   VANDF   WHO-DD  
Common Name English
PERCODAN-DEMI COMPONENT OXYCODONE TEREPHTHALATE
Common Name English
14-HYDROXYDIHYDROCODEINONE TEREPHTHALATE (2:1)
Common Name English
OXYCODONE TEREPHTHALATE COMPONENT OF CODOXY
Common Name English
MORPHINAN-6-ONE, 4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYL-, 1,4-BENZENEDICARBOXYLATE (2:1 SALT), (5.ALPHA.)
Common Name English
OXYCODONE TEREPHTHALATE COMPONENT OF PERCODAN-DEMI
Common Name English
CODOXY COMPONENT OXYCODONE TEREPHTHALATE
Common Name English
ROXIPRIN COMPONENT OXYCODONE TEREPHTHALATE
Common Name English
OXYCODONE TEREPHTHALATE [USP IMPURITY]
Common Name English
OXYCODONE TEREPHTHALATE [MART.]
Common Name English
OXYCODONE TEREPHTHALATE [USP MONOGRAPH]
Common Name English
4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one 1,4-benzenedicarboxylate (2:1 salt)
Common Name English
OXYCODONE TEREPHTHALATE [ORANGE BOOK]
Common Name English
OXYCODONE TEREPHTHALATE [VANDF]
Common Name English
OXYCODONE TEREPHTHALATE COMPONENT OF ROXIPRIN
Common Name English
Oxycodone terephthalate [WHO-DD]
Common Name English
Classification Tree Code System Code
DEA NO. 9143
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
NCI_THESAURUS C67413
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
NCI_THESAURUS C1506
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
Code System Code Type Description
EVMPD
SUB03585MIG
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
PRIMARY
ChEMBL
CHEMBL656
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
PRIMARY
SMS_ID
100000085510
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
PRIMARY
NCI_THESAURUS
C48009
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
PRIMARY
PUBCHEM
23724882
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
PRIMARY
WIKIPEDIA
Oxycodone terephthalate
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
PRIMARY
FDA UNII
M04XWV43UF
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
PRIMARY
DRUG BANK
DBSALT001326
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
PRIMARY
RXCUI
159821
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
PRIMARY RxNorm
MESH
C016026
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
PRIMARY
DAILYMED
M04XWV43UF
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
PRIMARY
CAS
124133-68-2
Created by admin on Wed Jul 05 22:50:40 UTC 2023 , Edited by admin on Wed Jul 05 22:50:40 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY